Breast Cancer
Conditions
Keywords
ER positive and HER2 positive, triple-targeted anti-HER2 strategy, chemotherapy-free, neoadjuvant
Brief summary
To further enhance treatment efficacy, minimize reliance on chemotherapy, and identify the optimal neoadjuvant approach for ER-positive and HER2-positive population, we have designed a single-arm, phase II clinical trial. This study aims to evaluate the efficacy and safety of a novel regimen integrating CDK4/6 inhibitors intensified endocrine therapy and dual HER2-targeted monoclonal antibodies plus the tyrosine kinase inhibitor pyrotinib.
Detailed description
In patients with ER-positive and HER2-positive breast cancer, the therapeutic potential of combining trastuzumab, pertuzumab, and pyrotinib-representing a triple-targeted anti-HER2 strategy-alongside intensified endocrine therapy( with CDK4/6 inhibitors )has not yet been established. To further enhance treatment efficacy, minimize reliance on chemotherapy, and identify the optimal neoadjuvant approach for this patient population, we have designed a single-arm, phase II clinical trial. This study aims to evaluate the efficacy and safety of a novel regimen integrating CDK4/6 inhibitors intensified endocrine therapy and dual HER2-targeted monoclonal antibodies plus the tyrosine kinase inhibitor pyrotinib.
Interventions
DRUGtriple-targeted anti-HER2 and CDK4/6 inhibitor
trastuzumab, pertuzumab, and pyrotinib combined with CDK4/6 inhibitor and endocrine therapy
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Women aged 18 to 70 years with breast cancer eligible for neoadjuvant therapy 2. Clinically staged as II-III 3. Histologically confirmed unilateral invasive breast cancer with HER2 positivity, defined as HER2 immunohistochemistry 3+ or in situ hybridization (FISH)-confirmed amplification 4. Estrogen receptor (ER) expression ≥10% by immunohistochemistry 5. Postmenopausal status 6. Premenopausal or perimenopausal patients must undergo surgical oophorectomy or receive ovarian function suppression with gonadotropin-releasing hormone (GnRH) agonists 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 8. Left ventricular ejection fraction (LVEF) ≥50% and corrected QT interval (QTc) ≤470 ms 9. Adequate major organ function, as evidenced by the following laboratory parameters: (1) Hematologic function: hemoglobin (Hb) ≥90 g/L (without transfusion within 14 days), absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count (PLT) ≥100×10⁹/L; (2) Hepatic and renal function: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN, serum creatinine ≤1×ULN, and calculated creatinine clearance \>50 mL/min using the Cockcroft-Gault formula 10) Willingness to participate in the study, provision of signed informed consent, and demonstrated ability to comply with study procedures and follow-up visits
Exclusion criteria
1. HER2-negative disease, defined as immunohistochemistry (IHC) score of 0 or 1+; or IHC 2+ without amplification by fluorescence in situ hybridization (FISH) 2. Prior receipt of neoadjuvant therapy or any systemic or non-surgical local treatment, including chemotherapy, targeted therapy, radiotherapy, or endocrine therapy 3. History of another malignancy, except for adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ 4. Inflammatory breast cancer, bilateral breast cancer, or presence of distant metastases 5. Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use effective contraception during the study period 6. Concurrent participation in another interventional clinical trial 7. Significant organ dysfunction, including cardiac, pulmonary, hepatic, or renal impairment; left ventricular ejection fraction (LVEF) \<50% on echocardiography; history of major cardiovascular or cerebrovascular events within 6 months prior to enrollment (e.g., unstable angina, chronic heart failure, myocardial infarction, or stroke); uncontrolled hypertension (\>150/90 mmHg); or poorly controlled diabetes mellitus 8. Current use of strong CYP3A4 inhibitors or inducers, including: 1. Strong inhibitors: boceprevir, clarithromycin, conivaptan, delavirdine, indinavir, itraconazole, ketoconazole, ritonavir, mibefradil, miconazole, trazodone, nelfinavir, posaconazole, saquinavir, telaprevir, telithromycin, voriconazole, grapefruit, grapefruit juice, or grapefruit-containing products 2. Strong inducers: carbamazepine, phenytoin, primidone, rifampicin, and St. John's wort 9. Active, severe, or uncontrolled infection, or fever of unknown origin during the screening period 10. History of substance abuse involving psychotropic agents with ongoing dependence, or history of significant psychiatric disorder that may impair compliance or safety 11. Deemed unsuitable for study participation by the treating investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR | 3 years | pathological response rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| iDFS | 3 years | invasive disease free survival |
| RFS | 3 years | Recurrence free survival |
| EFS | 3 years | Event free survival |
| OS | 3 years | overall survival |
| adverse events | 3 years | adverse events according to CTCAE 5.0 |
| DDFS | 3 years | distant disease free survival |
Contacts
Primary ContactZhimin Shao, MD, PhD
Backup ContactYin Liu, MD
Outcome results
None listed